[Fludarabine treatment of chronic lymphoid leukemia].
OBJECTIVE
To try effectiveness of fludarabine monotherapy in verified chronic lymphoid leukemia (CLL) in pretreated patients.


METHODS
The treatment effectiveness according to the international criteria of complete and partial remission was assessed in 37 patients with progressive, splenic, tumor and bone marrow forms of CLL given 5-day courses of fludarabine in a single daily dose 25 mg.


RESULTS
In progressive CLL, the remission was achieved in 45% of the patients (10% complete and 35% partial), in splenic form--62.5% (12.5% complete, 50% partial), in tumor form--50% (100% partial). In bone marrow form no remissions were obtained.


CONCLUSIONS
Fludarabine is effective in therapy of pretreated CLL patients. The treatment should be adjusted to CLL form.
Gabeeva
N G
NG
Pivnik
A V
AV
Moiseeva
T N
TN
Zybunova
E E
EE
Samoĭlova
R S
RS
Kremenetskaia
A M
AM
Varlamova
E Iu
EIu
Kaplanskaia
I B
IB
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001853:Bone Marrow / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D014740:Vidarabine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine